Pasar al contenido principal

IMPLICACIONES DE LA ELIMINACION ESPECIFICA DE TPL2 EN MACROFAGOS EN EL DESARROLLO DE LA ENFERMEDAD HEPATICA CRONICA

PID2020-113299RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

  • Gutiérrez, Alejandro H.
  • Mazariegos, Marina
  • Alemany, Susana
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Sanz-García, Carlos
The cytoplasmic protein tumor progression locus 2 (TPL2), also known as cancer Osaka thyroid (Cot), or MAP3K8, is thought to have a significant role in a variety of cancers and illnesses and it is a key component in the activation pathway for the expression of inflammatory mediators. Despite the tight connection between inflammation and TPL2, its function has not been extensively studied in chronic liver disease (CLD), a major cause of morbidity and mortality worldwide. Here, we analyze more in detail the significance of TPL2 in CLD to shed light on the pathological and molecular transduction pattern of TPL2 during the progression of CLD. This might result in important advancements and enable progress in the diagnosis and treatment of CLD., This work has received funding from the MICINN Retos PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2020-116146RB-I00 all of which were cofinanced with Fondos FEDER. The European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and COST Action CA17112. CSG is an Atracción de Talento (CAM) Researcher 2019-T1/BMD-13313., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

  • Lamas-Paz, Arantza
  • Hionides-Gutiérrez, Alejandro
  • Guo, Feifei
  • Jorquera, Gonzalo
  • Morán-Blanco, Laura
  • Benedé-Ubieto, Raquel
  • Mesquita, Mariana
  • Estévez-Vázquez, Olga
  • Zheng, Kang
  • Mazariegos, Marina
  • Vázquez-Ogando, Elena
  • Blázquez-López, Elena
  • Asensio, Iris
  • Mutlu, Beste
  • Gomez-Santos, Beatriz
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
  • Martínez-Naves, Eduardo
  • Sanz-García, Carlos
  • Mohamed, Mohamed Ramadan
  • Tesolato, Sofía
  • Iniesta, Pilar
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Martínez-Alcocer, Ana
  • Sanfeliu-Redondo, David
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andrea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Ávila, Matías A.
  • Frutos, Maria Dolores
  • Martínez-Cáceres, Carlos Manuel
  • Ramos-Molina, Bruno
  • Aspichueta, Patricia
  • Puigserver, Pere
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
[Background & Aims] Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of CDKN1A in SLD., [Methods] CDKN1A expression levels were evaluated in different patient cohorts with SLD, fibrosis, and advanced chronic liver disease (ACLD). Cdkn1a-/- and Cdkn1a+/+ mice were fed with either a Western diet (WD), a Lieber-DeCarli (LdC) diet plus multiple EtOH (ethanol) binges, or a DuAL diet (metabolic dysfunction-associated fatty liver disease and alcohol-related liver). Primary hepatocytes were isolated and functional assays performed., [Results] A significant increase in CDKN1A expression was observed in patients with steatohepatitis and fibrosis (with a positive correlation with both NAFLD Activity Score and fibrosis staging scores), cirrhosis and ACLD. Cdkn1a+/+ mice, fed a DuAL diet exhibited liver injury and cell death increased reactive oxygen species (ROS), and markers of senescence (γH2AX, β-GAL, Cdkn1a/p53) contributing to steatosis and inflammation. In contrast, Cdkn1a-/- mutant mice showed a significant decrease in senescence-associated markers as well as in markers of liver injury, hepatic steatosis and an increase in fatty acid oxidation and reduction in free fatty acid uptake as well as de novo lipogenesis. Mechanistically, activation of the AMPK-SIRT3 was observed in Cdkn1a-deleted animals., [Conclusions] Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis via the AMPK-SIRT3 axis. CDKN1A expression was found to be directly correlated with increased severity of NAFLD Activity Score and fibrosis in patients with SLD. CDKN1A could be a potential theragnostic target for the treatment of metabolic dysregulation in patients with SLD, with and without alcohol consumption., [Impact and implications] Expression of p21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD), but the molecular mechanisms remain elusive. Interestingly, in this study we found that Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis, via the AMPK-SIRT3 axis. Translationally, Cdkn1a expression was found to be directly correlated with increased severity of NAFLD Activity Score (NAS) and fibrosis in SLD patients, and therefore, CDKN1A might be used potential theragnostic target for the treatment of metabolically induced SLD, with and without alcohol consumption., This work was supported by the MICIU/AEI/10.13039/501100011033 PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2021-124425OB-I00, PID2023-150260OB-I00, and PID2023-151347OB-I00, all of which were co-financed with Fondos FEDER, UE, Basque Government, Department of Education (IT1476-2), the Institute of Health Carlos III (ISCIII) (awards numbers PI20/00505 and PI23/00171), EXOHEP2-CM (S2022/BMD-7409), HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and the Dynamic Resilience Program - Wellcome Leap. CSG is an Atracción de Talento (CAM) 2019 2019-T1/BMD-13313. The research group belongs to the validated Research Groups Ref. 970935 ‘Liver Pathophysiology’, 920631 ‘Lymphocyte immunobiology’, 920361 ‘Inmunogenética e inmunología de las mucosas’ and IBL-6 (imas12-associated). ALP and AH are recipients of a UCM Real Colegio Complutense (RCC) Harvard - Santander scholarships CT17/17 and CT15/23, respectively. BRM is supported by the ‘Miguel Servet Type I’ program (CP19/00098, funded by the Institute of Health Carlos III, Spain; co-funded by the ‘Fondo Europeo de Desarrollo Regional’)., Peer reviewed